Evolus (EOLS) Notes Payables (2017 - 2021)

Evolus (EOLS) reported Notes Payables of $20.0 million for Q3 2021, up 1.54% quarter-over-quarter from $19.6 million in Q2 2021.

Evolus (EOLS) Notes Payables (2017 - 2021) Analysis & Trends

Evolus has reported Notes Payables for 3 years, with the latest figure at $20.0 million in Q3 2021.

  • For the quarter ending Q3 2021, Notes Payables changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Sep 2021 stood at $20.0 million (changed N/A YoY), and the FY2020 full-year result was $19.1 million, changed N/A from the prior year.
  • Notes Payables for Q3 2021 stood at $20.0 million, up from $19.6 million in the prior quarter.
  • The five-year high for Notes Payables was $138.7 million in Q4 2017, with the low at $19.1 million in Q4 2020.
  • Historically, Notes Payables has averaged $43.3 million across 3 years, with a median of $19.6 million in 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn
10 Evolus 435.45 Mn 385.65 Mn 48.90 Mn

Historic Data

Download Data
DateValue
Sep 30, 2021 19.95 Mn
Jun 30, 2021 19.65 Mn
Mar 31, 2021 19.35 Mn
Dec 31, 2020 19.07 Mn
Dec 31, 2017 138.69 Mn